摘要
目的:评价雷帕霉素洗脱支架在冠状动脉慢性(闭塞时间≥3个月)闭塞性病变治疗中的疗效。方法:86例冠状动脉造影显示慢性闭塞性病变患者,在成功重建冠状动脉血运后置入雷帕霉素洗脱支架(CypherTM, Cordis,Johnson & Johnson)50例(SES组),裸金属支架36例(BMS组),比较两组术后1年内各种不良心脏事件(死亡、心肌梗死、再次血管重建术和支架内血栓形成)的发生情况和再狭窄、再闭塞发生率。结果:SES组不良心脏事件发生率较BMS组显著降低(4．0％vs 19．4％,P<0．05)。SES组和BMS组分别有17例 (34．0％)和13例(36．1％)患者行冠状动脉造影复查,SES组较BMS组晚期丧失[(0．18±0．54)mm vs(0．85±0．98) mm,P<0．05]和再狭窄率(11．8％ vs 46．2％,P<0．05)显著降低。结论:雷帕霉素洗脱支架在冠状动脉慢性闭塞性病变治疗中可显著降低不良心脏事件的发生率和再狭窄发生率。
Objective： To assess the efficacy of drug-eluting stent implantation in patients with chronic coronary total occlusion （CTO）.
Methods： In 50 consecutive patients, sirolimus-eluting stents （SES group） （Cypher, Cordis, Johnson ＆ Johnson）were implanted after successful recanalization of CTO. They were compared with 36 matched CTO patients treated with bare metal stents （BMS group）. The study end points were the one-year incidence of major adverse cardiac events （MACE） （death, myocardial infarction, repeat revascularization） and the rates of restenosis and re-occlusion.
Results： Clinical follow-up data were available for all patients in the two groups. The SES group had fewer MACE than BMS group （4.0% vs 19. 4% ,P 〈0.05 ）. Angiographic follow-up was performed in 34.0% of SES group patients and in 36. 1% of the BMS group patients. The restenosis rate was 11.8% in the SES group and 46. 2% in the BMS group（ P 〈 0. 05 ）. The late loss in the SES group was significantly lower than in the BMS group （0. 18 ±0. 54 mm vs 0. 85 ± 0. 98 mm, P 〈 0. 05 ）.
Conclusion ： Sirolimus-eluting stent implantation after recanalization of chronic coronary total occlusion provides a better clinical outcome with less MACE and restenosis.
出处
《中国循环杂志》
CSCD
北大核心
2006年第2期110-112,共3页
Chinese Circulation Journal
